We are dedicated to helping people with diabetes lead a healthy life.ABOUT
Top
Company Profile
The Leader in Diabetes Technology

Established in 2011, MicroTech Medical is located in the Hangzhou Future Sci-Tech City, which is the leading venture technology park in Hangzhou. Shortly after, the US R&D center was established in California’s Silicon Valley.

MicroTech’s management and technical teams were recruited from all over the world, with the majority of the group having post-secondary, graduate and/or post-graduate university degrees as well as extensive experience in medical technology.

MicroTech’s certifications include regulatory approvals for CE and CFDA, as well as product conformity to ISO 15197:2015 (BGMS products) and IEC 60601-2-24 (pump therapy products). In 2013, the government designated MicroTech as Lead Diabetes Research Center in Zhejiang Province.

MicroTech Medical is devoted to innovation in chronic disease management, and strives to bring to market healthcare products globally. The company’s portfolio includes therapy products such as the Equil Patch Insulin Pump and diagnostic products such as the AiDEX Continuous Glucose Monitoring System (CGMS), multiple lines of Blood Glucose Monitoring Systems (BGMS), and POCT products.

With the help this line of products, MicroTech Medical continues to allow more freedom, flexibility, and choice to those who are limited by chronic disease.

Milestone
Products have been sold to customers in over 20 countries - all over the world
MTM DiabeteCare Germany MicroTech MD LTD China MicroTech MD Inc USA
  • 2011
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
  • 2019
2011
Microtech Medical Established In Hangzhou, China
2013
CFDA Approves Manufacturing Site For Ivd/Pump Products
2014
Microtech Medical, Inc. Founded In Silicon Valley, USA Tuv Approves Quality System Compliance for Ce Mark.
2015
God Bgms Launched In Eu
2016
Gdh Bgms Launched In China
2017
Patch Insulin Pump Launched
2018
Patch Insulin Pump Launched In Eu (Italy, Greece, And Others)
2019
Q3 Cgms Will Be Launched